Some advocacy groups and lawmakers are urging FDA not to revoke its approval of Roche's Avastin for treatment of advanced breast cancer, arguing that such a decision would limit women's access to the drug by prompting insurers to reject coverage for it, the Fiscal Times/Kaiser Health News reports...
More...